May 17, 2023

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect

January 09, 2023

Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction

December 05, 2022

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

December 05, 2022

Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM

October 10, 2022

Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase

September 15, 2022

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium

August 26, 2022

Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022

August 26, 2022

IMPROVE DiCE: A Phase 2a Trial Investigating Ninerafaxstat - A Novel Cardiac Mitotrope for the treatment of Diabetic Cardiomyopathy

August 22, 2022

Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022

March 24, 2022

Imbria Appoints John Young to its Board of Directors

March 22, 2022

Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect

March 10, 2022

Imbria Pharmaceuticals Strengthens Executive Leadership Team with New Appointments

July 19, 2021

Imbria Pharmaceuticals Announces initiation of enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the safety, tolerability, and efficacy of IMB-1018972 (IMB-101) in patients with non-obstructive hypertrophic cardiomyopathy

July 05, 2021

IMB-10189721, a novel first-in-class partial fatty acid oxidation (pFOX) inhibitor improves cardiac remodelling and function post-myocardial infarction.

July 05, 2021

Phase 1 safety and tolerability study of IMB-1018972, a novel oral modulator of substrate utilization designed to improve cardiac metabolic efficiency and bioenergetics

June 22, 2021

Imbria Pharmaceuticals announces enrolment of the first 10 patients in IMPROVE-DiCE, an exploratory Phase 2 study investigating the impact of IMB-1018972 on cardiac energetics, metabolism and function in patients with type 2 diabetes